<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04020263</url>
  </required_header>
  <id_info>
    <org_study_id>2019-001563-74</org_study_id>
    <nct_id>NCT04020263</nct_id>
  </id_info>
  <brief_title>Effect of Early Use of Levosimendan Versus Placebo on Top of a Conventional Strategy of Inotrope Use on a Combined Morbidity-mortality Endpoint in Patients With Cardiogenic Shock</brief_title>
  <acronym>LevoHeartShock</acronym>
  <official_title>Effect of Early Use of Levosimendan Versus Placebo on Top of a Conventional Strategy of Inotrope Use on a Combined Morbidity-mortality Endpoint in Patients With Cardiogenic Shock</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cardiogenic shock (CS) mortality remains high (40%). Despite their frequent use, few clinical
      outcome data are available to guide the initial selection of vasoactive drug therapies in
      patients with CS. Based on experts' opinions, the combination of norepinephrine-dobutamine is
      generally recommended as a first line strategy. Inotropic agents increase myocardial
      contractility, thereby increasing cardiac output. Dobutamine is commonly recommended to be
      the inotropic agent of choice and levosimendan is generally used following dobutamine
      failure. It may represent an ideal agent in cardiogenic shock, since it improves myocardial
      contractility without increasing cAMP or calcium concentration. At present, there are no
      convincing data to support a specific inotropic agent in patients with cardiogenic shock. Our
      hypothesis is that the early use of levosimendan, by enabling the discontinuation of
      dobutamine, would accelerate the resolution of signs of low cardiac output and facilitate
      myocardial recovery.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2019</start_date>
  <completion_date type="Anticipated">June 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The LevoHeartShock trial is a prospective, double-blind, multicenter, randomized controlled trial comparing the early initiation of levosimendan versus placebo in patients with cardiogenic shock treated with vasopressor therapy according to a conventional strategy of inotrope use (dobutamine as first line agent).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>The study will be double-blinded. Investigator masking to group assignment after randomization will be guaranteed by use of a placebo. The packaging and labeling of placebo and levosimendan vials will be similar to guarantee the double blinded aspect.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of All-cause mortality</measure>
    <time_frame>Day 30 following randomization</time_frame>
    <description>Composite endpoint (i.e. All-cause Mortality and/or Extra Corporel Life Support implantation and/or dialysis)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of Extra Corporel Life Support implantation</measure>
    <time_frame>Day 30 following randomization</time_frame>
    <description>Composite endpoint (i.e. All-cause Mortality and/or Extra Corporel Life Support implantation and/or dialysis)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of Dialysis</measure>
    <time_frame>Day 30 following randomization</time_frame>
    <description>Composite endpoint (i.e. All-cause Mortality and/or Extra Corporel Life Support implantation and/or dialysis)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of All-cause mortality</measure>
    <time_frame>Days 7, 30, 60, 90, 180</time_frame>
    <description>Composite endpoint (i.e. All-cause Mortality and/or Extra Corporel Life Support implantation and/or dialysis)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Extra Corporel Life Support implantation</measure>
    <time_frame>Days 7, 30, 60, 90, 180</time_frame>
    <description>Composite endpoint (i.e. All-cause Mortality and/or Extra Corporel Life Support implantation and/or dialysis)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of dialysis</measure>
    <time_frame>Days 7, 30, 60, 90, 180</time_frame>
    <description>Composite endpoint (i.e. All-cause Mortality and/or Extra Corporel Life Support implantation and/or dialysis)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of death</measure>
    <time_frame>Days 30, 60, 90, 180 and 12 months</time_frame>
    <description>Composite endpoint of major adverse cardiovascular events defined as death, cardiac transplantation, escalation to permanent left ventricular assist device, stroke, recurrent myocardial infarction, urgent coronary revascularization, dialysis, re-hospitalization for heart failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of cardiac transplantation</measure>
    <time_frame>Days 30, 60, 90, 180 and 12 months</time_frame>
    <description>Composite endpoint of major adverse cardiovascular events defined as death, cardiac transplantation, escalation to permanent left ventricular assist device, stroke, recurrent myocardial infarction, urgent coronary revascularization, dialysis, re-hospitalization for heart failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of escalation to permanent Left Ventricular Assist Device</measure>
    <time_frame>Days 30, 60, 90, 180 and 12 months</time_frame>
    <description>Composite endpoint of major adverse cardiovascular events defined as death, cardiac transplantation, escalation to permanent left ventricular assist device, stroke, recurrent myocardial infarction, urgent coronary revascularization, dialysis, re-hospitalization for heart failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of stroke</measure>
    <time_frame>Days 30, 60, 90, 180 and 12 months</time_frame>
    <description>Composite endpoint of major adverse cardiovascular events defined as death, cardiac transplantation, escalation to permanent left ventricular assist device, stroke, recurrent myocardial infarction, urgent coronary revascularization, dialysis, re-hospitalization for heart failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of recurrent myocardial infarction</measure>
    <time_frame>Days 30, 60, 90, 180 and 12 months</time_frame>
    <description>Composite endpoint of major adverse cardiovascular events defined as death, cardiac transplantation, escalation to permanent left ventricular assist device, stroke, recurrent myocardial infarction, urgent coronary revascularization, dialysis, re-hospitalization for heart failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of urgent coronary revascularization</measure>
    <time_frame>Days 30, 60, 90, 180 and 12 months</time_frame>
    <description>Composite endpoint of major adverse cardiovascular events defined as death, cardiac transplantation, escalation to permanent left ventricular assist device, stroke, recurrent myocardial infarction, urgent coronary revascularization, dialysis, re-hospitalization for heart failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of dialysis</measure>
    <time_frame>Days 30, 60, 90, 180 and 12 months</time_frame>
    <description>Composite endpoint of major adverse cardiovascular events defined as death, cardiac transplantation, escalation to permanent left ventricular assist device, stroke, recurrent myocardial infarction, urgent coronary revascularization, dialysis, re-hospitalization for heart failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of re-hospitalization for heart failure</measure>
    <time_frame>Days 30, 60, 90, 180 and 12 months</time_frame>
    <description>Composite endpoint of major adverse cardiovascular events defined as death, cardiac transplantation, escalation to permanent left ventricular assist device, stroke, recurrent myocardial infarction, urgent coronary revascularization, dialysis, re-hospitalization for heart failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of administered dobutamine</measure>
    <time_frame>From baseline to Intensive Care Unit discharge (assessed up to 1 month)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of administered dobutamine</measure>
    <time_frame>From baseline to Intensive Care Unit discharge (assessed up to 1 month)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration with abnormal lactate value</measure>
    <time_frame>From baseline to Intensive Care Unit discharge (assessed up to 1 month)</time_frame>
    <description>Lactate Clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days with organ failure(s)</measure>
    <time_frame>From baseline to Intensive Care Unit discharge (assessed up to 1 month)</time_frame>
    <description>Defined with the SOFA score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of days between inclusion and D30, without organ failure</measure>
    <time_frame>From baseline to day 30</time_frame>
    <description>Defined with the SOFA score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of catecholamine hemodynamic support</measure>
    <time_frame>From baseline to Intensive Care Unit discharge (assessed up to 1 month)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of days between inclusion and D30 without hemodynamic support</measure>
    <time_frame>From baseline to day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of mechanical ventilation</measure>
    <time_frame>From baseline to Intensive Care Unit discharge (assessed up to 1 month)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of days alive without mechanical ventilation</measure>
    <time_frame>From baseline to day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of intensive care unit stay</measure>
    <time_frame>Up to Intensive Care Unit discharge (assessed up to 1 month)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospitalization</measure>
    <time_frame>Up to hospitalization discharge (assessed up to 1 month)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of arrhythmias</measure>
    <time_frame>From baseline to Intensive Care Unit discharge (assessed up to 1 month)</time_frame>
    <description>Including atrial fibrillation and other arrhythmias, ventricular tachycardia, ventricular fibrillation, torsade de pointe</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">610</enrollment>
  <condition>Cardiogenic Shock</condition>
  <arm_group>
    <arm_group_label>Levosimendan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental group: patients with cardiogenic shock treated with levosimendan in addition to the conventional strategy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Control group: Patients with cardiogenic shock treated with placebo for levosimendan in addition to the conventional strategy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levosimendan 2.5 MG/ML Injectable Solution</intervention_name>
    <description>Levosimendan will be diluted with Glucose G5%. The reconstitution of levosimendan will be performed, as close as possible to the start of the infusion. A continuous infusion of levosimendan will be administered over 24 h without bolus, started at a rate of 0.1 μg per kilogram of body weight per minute and, in both the persistence of hypoperfusion signs and in the absence of rate-limiting side effects, will be increased after 2 to 4 hours to a maximum of 0.2 μg per kilogram per minute for a further 20 to 22 hours.</description>
    <arm_group_label>Levosimendan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be diluted with Glucose G5%. The reconstitution of Placebo will be performed, as close as possible to the start of the infusion. A continuous infusion of Placebo will be administered over 24 h without bolus, started at a rate of 0.1 μg per kilogram of body weight per minute and, in both the persistence of hypoperfusion signs and in the absence of rate-limiting side effects, will be increased after 2 to 4 hours to a maximum of 0.2 μg per kilogram per minute for a further 20 to 22 hours.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Adult patient with cardiogenic shock defined by:

          -  Adequate intravascular volume

          -  Norepinephrine infusion &lt;1 microgram/kg/min to maintain MAP at least at 65 mmHg for at
             least 3 hours and less than 12h or dobutamine ≥ 5 microgram/kg/min since at least 3h
             and less than 12h

          -  Tissue hypoperfusion: at least 2 signs (lactate ≥ 2 mmol/l, mottling, oliguria, ScVO2
             ≤ 60% or veno-arterial PCO2 gap ≥ 5 mmHg)

          -  Clinical pulmonary congestion or elevated natriuretic peptides or echocardiographic
             sign of elevated left ventricular pressure or elevated right atrial pressure.

        Exclusion Criteria:

          -  Myocardial sideration after cardiac arrest of non-cardiac etiology

          -  Immediate or anticipated (within 6 hours) indication of Extra Corporel Life Support

          -  Extra Corporel Life Support (Extracorporeal Membrane Oxygenation (ECMO) or Impella)

          -  Chronic renal failure requiring hemodialysis

          -  Cardiotoxic poisoning

          -  Septic cardiomyopathy

          -  Previous levosimendan administration within 15 days

          -  Cardiac arrest resuscitation &gt;30 minutes

          -  Cerebral deficit with fixed dilated pupils

          -  Patient moribund on the day of randomization

          -  Irreversible neurological pathology

          -  Known hypersensitivity to levosimendan or placebo, or one of its excipients

          -  Woman of childbearing age without effective contraception

          -  Persons referred in articles L.1121-5 to L.1121-8 and L.1122-2 of the Public Health
             Code:

               -  Pregnant, parturient or breastfeeding woman

               -  Person deprived of liberty for judicial or administrative decision

               -  Person under psychiatric care

               -  Minor person (non-emancipated)

               -  Adult person under legal protection (any form of public guardianship)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clément DELMAS, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>CHU Toulouse</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nicolas GIRERD, Pr</last_name>
    <role>Study Chair</role>
    <affiliation>CHRU Nancy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patrick ROSSIGNOL, Pr</last_name>
    <role>Study Chair</role>
    <affiliation>CHRU Nancy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bruno LEVY, Pr</last_name>
    <phone>+33 3 83 15 40 84</phone>
    <email>b.levy@chru-nancy.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHRU Strasbourg -Nouvel Hôpital Civil</name>
      <address>
        <city>Strasbourg</city>
        <state>Bas-Rhin</state>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Ferhat Meziani, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ferhat Meziani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HM, la Timone Hospital, Marseille</name>
      <address>
        <city>Marseille</city>
        <state>Bouches Du Rhône</state>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Marc Gainnier, MD</last_name>
    </contact>
    <investigator>
      <last_name>Marc Gainnier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HM, Nord Hospital, Marseille</name>
      <address>
        <city>Marseille</city>
        <state>Bouches Du Rhône</state>
        <zip>13015</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Laurent Bonello, MD</last_name>
    </contact>
    <investigator>
      <last_name>Laurent Bonello, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Caen</name>
      <address>
        <city>Caen</city>
        <state>Calvados</state>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Katrien Blanchart, MD</last_name>
    </contact>
    <investigator>
      <last_name>Katrien Blanchart, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Dijon, BOCAGE Hospital</name>
      <address>
        <city>Dijon</city>
        <state>Côte d'Or</state>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Jean-Pierre Quenot, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Pierre Quenot, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Besançon Jean Minjoz Hospital</name>
      <address>
        <city>Besançon</city>
        <state>Doubs</state>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Gilles Capellier, MD</last_name>
    </contact>
    <investigator>
      <last_name>Gilles Capellier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nîmes, Carémeau Hospital</name>
      <address>
        <city>Nîmes</city>
        <state>Gard</state>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Benoît Lattuca, MD</last_name>
    </contact>
    <investigator>
      <last_name>Benoît Lattuca, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux - Hopital haut-leveque</name>
      <address>
        <city>Bordeaux</city>
        <state>Gironde</state>
        <zip>33600</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Edouard Gerbaud, MD</last_name>
    </contact>
    <investigator>
      <last_name>Edouard Gerbaud, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <state>Haute-Garonne</state>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Clément Delmas, MD</last_name>
    </contact>
    <investigator>
      <last_name>Clément Delmas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Limoges, Dupuytren Hospital</name>
      <address>
        <city>Limoges</city>
        <state>Haute-Vienne</state>
        <zip>87000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Philippe Vignon, MD</last_name>
    </contact>
    <investigator>
      <last_name>Philippe Vignon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Montpellier, Arnaud de Villeneuve Hospital</name>
      <address>
        <city>Montpellier</city>
        <state>Hérault</state>
        <zip>34090</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>François Roubille, MD</last_name>
    </contact>
    <investigator>
      <last_name>François Roubille, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Montpellier, site Lapeyronie</name>
      <address>
        <city>Montpellier</city>
        <state>Hérault</state>
        <zip>34090</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Kada Klouche, MD</last_name>
    </contact>
    <investigator>
      <last_name>Kada Klouche, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Rennes, Pontchaillou Hospital</name>
      <address>
        <city>Rennes</city>
        <state>Ille Et Vilaine</state>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Guillaume Leurent, MD</last_name>
    </contact>
    <investigator>
      <last_name>Guillaume Leurent, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble, Michallon Hospital</name>
      <address>
        <city>La Tronche</city>
        <state>Isère</state>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Nicolas Terzi, MD</last_name>
    </contact>
    <investigator>
      <last_name>Nicolas Terzi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nantes - Hôtel Dieu</name>
      <address>
        <city>Nantes</city>
        <state>Loire-Atlantique</state>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Jean Reignier, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jean Reignier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHR Metz-Thionville, Mercy Hospital</name>
      <address>
        <city>Ars-Laquenexy</city>
        <state>Moselle</state>
        <zip>57245</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Guillaume Louis, MD</last_name>
    </contact>
    <investigator>
      <last_name>Guillaume Louise, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Lille, Cœur Poumon Institute</name>
      <address>
        <city>Lille</city>
        <state>Nord</state>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Nicolas Lamblin, MD</last_name>
    </contact>
    <investigator>
      <last_name>Nicolas Lamblin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHP, Raymond Poincaré Hospital</name>
      <address>
        <city>Garches</city>
        <state>Paris</state>
        <zip>92380</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Djillali Annane, MD</last_name>
    </contact>
    <investigator>
      <last_name>Djillali Annane, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Clermont- Ferrand Gabriel-Montpied</name>
      <address>
        <city>Clermont- Ferrand</city>
        <state>Puy-de-Dôme</state>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Elisabeth Coupez, MD</last_name>
    </contact>
    <investigator>
      <last_name>Elisabeth Coupez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospices Civils de Lyon - Louis Pradel Hospital</name>
      <address>
        <city>Bron</city>
        <state>Rhône</state>
        <zip>69500</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Eric Bonnefoy, MD</last_name>
    </contact>
    <investigator>
      <last_name>Eric Bonnefoy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Rouen, Charles Nicolle Hospital</name>
      <address>
        <city>Rouen</city>
        <state>Seine Maritime</state>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Fabienne Tamion, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Emmanuel Besnier, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Fabienne Tamion, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHP, Henri Mondor Hospital</name>
      <address>
        <city>Créteil</city>
        <state>Val De Marne</state>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Pascal Lim, MD</last_name>
    </contact>
    <investigator>
      <last_name>Pascal LIM, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Henri Duffaut, Avignon</name>
      <address>
        <city>Avignon</city>
        <state>Vaucluse</state>
        <zip>84000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Stéphane Andrieu, MD</last_name>
    </contact>
    <investigator>
      <last_name>Stéphane Andrieu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHP -Lariboisière Hospital (Cardiology department)</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Stephane Menzo-Silberman</last_name>
    </contact>
    <investigator>
      <last_name>Stephane Menzo-Silberman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHP, Lariboisière Hospital (intensive care unit and toxicology)</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Bruno Megarbane, MD</last_name>
    </contact>
    <investigator>
      <last_name>Bruno Megarbane, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHP, La Pitié Salpêtrière (medical intensive care unit)</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Alain Combes, MD</last_name>
    </contact>
    <investigator>
      <last_name>Alain Combes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHP- HEGP Paris</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Nadia Aissaoui Balanant, MD</last_name>
    </contact>
    <investigator>
      <last_name>Nadia Aissaoui Balanant, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Nancy</name>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Bruno Lévy, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Bruno LEVY, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>June 28, 2019</study_first_submitted>
  <study_first_submitted_qc>July 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2019</study_first_posted>
  <last_update_submitted>July 16, 2019</last_update_submitted>
  <last_update_submitted_qc>July 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>heart failure</keyword>
  <keyword>levosimendan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Cardiogenic</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simendan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

